nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—lung cancer	0.254	1	CbGaD
Dihydroergotamine—ABCB1—Topotecan—lung cancer	0.0402	0.0864	CbGbCtD
Dihydroergotamine—ABCB1—Gefitinib—lung cancer	0.0368	0.079	CbGbCtD
Dihydroergotamine—ABCB1—Vinorelbine—lung cancer	0.0283	0.0609	CbGbCtD
Dihydroergotamine—CYP3A4—Topotecan—lung cancer	0.0241	0.0518	CbGbCtD
Dihydroergotamine—ABCB1—Crizotinib—lung cancer	0.0225	0.0484	CbGbCtD
Dihydroergotamine—CYP3A4—Gefitinib—lung cancer	0.022	0.0473	CbGbCtD
Dihydroergotamine—ABCB1—Gemcitabine—lung cancer	0.022	0.0473	CbGbCtD
Dihydroergotamine—ABCB1—Erlotinib—lung cancer	0.0217	0.0467	CbGbCtD
Dihydroergotamine—CYP3A4—Teniposide—lung cancer	0.0214	0.0459	CbGbCtD
Dihydroergotamine—ABCB1—Paclitaxel—lung cancer	0.0199	0.0428	CbGbCtD
Dihydroergotamine—ABCB1—Irinotecan—lung cancer	0.0196	0.0422	CbGbCtD
Dihydroergotamine—ABCB1—Vinblastine—lung cancer	0.0175	0.0375	CbGbCtD
Dihydroergotamine—CYP3A4—Vinorelbine—lung cancer	0.017	0.0365	CbGbCtD
Dihydroergotamine—ABCB1—Cisplatin—lung cancer	0.016	0.0344	CbGbCtD
Dihydroergotamine—ABCB1—Etoposide—lung cancer	0.0157	0.0338	CbGbCtD
Dihydroergotamine—ABCB1—Docetaxel—lung cancer	0.0144	0.0309	CbGbCtD
Dihydroergotamine—CYP3A4—Crizotinib—lung cancer	0.0135	0.029	CbGbCtD
Dihydroergotamine—CYP3A4—Erlotinib—lung cancer	0.013	0.028	CbGbCtD
Dihydroergotamine—CYP3A4—Paclitaxel—lung cancer	0.0119	0.0256	CbGbCtD
Dihydroergotamine—CYP3A4—Irinotecan—lung cancer	0.0118	0.0253	CbGbCtD
Dihydroergotamine—ABCB1—Doxorubicin—lung cancer	0.0107	0.023	CbGbCtD
Dihydroergotamine—CYP3A4—Vinblastine—lung cancer	0.0105	0.0225	CbGbCtD
Dihydroergotamine—ABCB1—Methotrexate—lung cancer	0.0104	0.0223	CbGbCtD
Dihydroergotamine—CYP3A4—Etoposide—lung cancer	0.00942	0.0202	CbGbCtD
Dihydroergotamine—CYP3A4—Docetaxel—lung cancer	0.00862	0.0185	CbGbCtD
Dihydroergotamine—CYP3A4—Doxorubicin—lung cancer	0.00642	0.0138	CbGbCtD
Dihydroergotamine—Arthralgia—Paclitaxel—lung cancer	0.000187	0.000872	CcSEcCtD
Dihydroergotamine—Myalgia—Paclitaxel—lung cancer	0.000187	0.000872	CcSEcCtD
Dihydroergotamine—Hypotension—Cisplatin—lung cancer	0.000186	0.000869	CcSEcCtD
Dihydroergotamine—Anxiety—Paclitaxel—lung cancer	0.000186	0.000869	CcSEcCtD
Dihydroergotamine—Face oedema—Doxorubicin—lung cancer	0.000186	0.000868	CcSEcCtD
Dihydroergotamine—Decreased appetite—Gemcitabine—lung cancer	0.000186	0.000868	CcSEcCtD
Dihydroergotamine—Nausea—Topotecan—lung cancer	0.000185	0.000863	CcSEcCtD
Dihydroergotamine—Discomfort—Paclitaxel—lung cancer	0.000184	0.000861	CcSEcCtD
Dihydroergotamine—Fatigue—Gemcitabine—lung cancer	0.000184	0.00086	CcSEcCtD
Dihydroergotamine—Confusional state—Etoposide—lung cancer	0.000184	0.000859	CcSEcCtD
Dihydroergotamine—Pain—Gemcitabine—lung cancer	0.000183	0.000853	CcSEcCtD
Dihydroergotamine—Nausea—Erlotinib—lung cancer	0.000183	0.000853	CcSEcCtD
Dihydroergotamine—Dry mouth—Paclitaxel—lung cancer	0.000183	0.000852	CcSEcCtD
Dihydroergotamine—Diarrhoea—Vinorelbine—lung cancer	0.000182	0.00085	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000181	0.000847	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Irinotecan—lung cancer	0.000181	0.000844	CcSEcCtD
Dihydroergotamine—Confusional state—Paclitaxel—lung cancer	0.00018	0.000843	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Irinotecan—lung cancer	0.000179	0.000838	CcSEcCtD
Dihydroergotamine—Oedema—Paclitaxel—lung cancer	0.000179	0.000836	CcSEcCtD
Dihydroergotamine—Paraesthesia—Cisplatin—lung cancer	0.000179	0.000835	CcSEcCtD
Dihydroergotamine—Muscle spasms—Docetaxel—lung cancer	0.000179	0.000834	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Methotrexate—lung cancer	0.000179	0.000834	CcSEcCtD
Dihydroergotamine—Tachycardia—Etoposide—lung cancer	0.000178	0.000832	CcSEcCtD
Dihydroergotamine—Dyspnoea—Cisplatin—lung cancer	0.000178	0.000829	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Etoposide—lung cancer	0.000176	0.000824	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Gemcitabine—lung cancer	0.000176	0.000822	CcSEcCtD
Dihydroergotamine—Shock—Paclitaxel—lung cancer	0.000176	0.000822	CcSEcCtD
Dihydroergotamine—Dizziness—Vinorelbine—lung cancer	0.000176	0.000821	CcSEcCtD
Dihydroergotamine—Tachycardia—Paclitaxel—lung cancer	0.000175	0.000815	CcSEcCtD
Dihydroergotamine—Anorexia—Etoposide—lung cancer	0.000174	0.000812	CcSEcCtD
Dihydroergotamine—Abdominal pain—Irinotecan—lung cancer	0.000173	0.00081	CcSEcCtD
Dihydroergotamine—Body temperature increased—Irinotecan—lung cancer	0.000173	0.00081	CcSEcCtD
Dihydroergotamine—Decreased appetite—Cisplatin—lung cancer	0.000173	0.000809	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Paclitaxel—lung cancer	0.000173	0.000808	CcSEcCtD
Dihydroergotamine—Anorexia—Paclitaxel—lung cancer	0.000171	0.000796	CcSEcCtD
Dihydroergotamine—Hypotension—Etoposide—lung cancer	0.000171	0.000796	CcSEcCtD
Dihydroergotamine—Pain—Cisplatin—lung cancer	0.00017	0.000795	CcSEcCtD
Dihydroergotamine—Muscular weakness—Doxorubicin—lung cancer	0.00017	0.000793	CcSEcCtD
Dihydroergotamine—Vomiting—Vinorelbine—lung cancer	0.000169	0.00079	CcSEcCtD
Dihydroergotamine—Body temperature increased—Gemcitabine—lung cancer	0.000169	0.000789	CcSEcCtD
Dihydroergotamine—Rash—Vinorelbine—lung cancer	0.000168	0.000783	CcSEcCtD
Dihydroergotamine—Dermatitis—Vinorelbine—lung cancer	0.000168	0.000783	CcSEcCtD
Dihydroergotamine—Hypotension—Paclitaxel—lung cancer	0.000167	0.000781	CcSEcCtD
Dihydroergotamine—Headache—Vinorelbine—lung cancer	0.000167	0.000778	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Methotrexate—lung cancer	0.000167	0.000778	CcSEcCtD
Dihydroergotamine—Dysphagia—Doxorubicin—lung cancer	0.000166	0.000777	CcSEcCtD
Dihydroergotamine—Palpitations—Docetaxel—lung cancer	0.000164	0.000767	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Cisplatin—lung cancer	0.000164	0.000767	CcSEcCtD
Dihydroergotamine—Paraesthesia—Etoposide—lung cancer	0.000164	0.000765	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000163	0.000761	CcSEcCtD
Dihydroergotamine—Dyspnoea—Etoposide—lung cancer	0.000163	0.00076	CcSEcCtD
Dihydroergotamine—Somnolence—Etoposide—lung cancer	0.000162	0.000758	CcSEcCtD
Dihydroergotamine—Angina pectoris—Doxorubicin—lung cancer	0.000162	0.000757	CcSEcCtD
Dihydroergotamine—Insomnia—Paclitaxel—lung cancer	0.000162	0.000756	CcSEcCtD
Dihydroergotamine—Epistaxis—Methotrexate—lung cancer	0.000162	0.000755	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Irinotecan—lung cancer	0.000162	0.000755	CcSEcCtD
Dihydroergotamine—Paraesthesia—Paclitaxel—lung cancer	0.000161	0.00075	CcSEcCtD
Dihydroergotamine—Hypertension—Docetaxel—lung cancer	0.00016	0.000749	CcSEcCtD
Dihydroergotamine—Bronchitis—Doxorubicin—lung cancer	0.00016	0.000748	CcSEcCtD
Dihydroergotamine—Dyspnoea—Paclitaxel—lung cancer	0.00016	0.000745	CcSEcCtD
Dihydroergotamine—Somnolence—Paclitaxel—lung cancer	0.000159	0.000743	CcSEcCtD
Dihydroergotamine—Decreased appetite—Etoposide—lung cancer	0.000159	0.000741	CcSEcCtD
Dihydroergotamine—Arthralgia—Docetaxel—lung cancer	0.000158	0.000739	CcSEcCtD
Dihydroergotamine—Myalgia—Docetaxel—lung cancer	0.000158	0.000739	CcSEcCtD
Dihydroergotamine—Nausea—Vinorelbine—lung cancer	0.000158	0.000738	CcSEcCtD
Dihydroergotamine—Dyspepsia—Paclitaxel—lung cancer	0.000157	0.000736	CcSEcCtD
Dihydroergotamine—Body temperature increased—Cisplatin—lung cancer	0.000157	0.000735	CcSEcCtD
Dihydroergotamine—Asthenia—Irinotecan—lung cancer	0.000157	0.000735	CcSEcCtD
Dihydroergotamine—Fatigue—Etoposide—lung cancer	0.000157	0.000735	CcSEcCtD
Dihydroergotamine—Pain—Etoposide—lung cancer	0.000156	0.000729	CcSEcCtD
Dihydroergotamine—Decreased appetite—Paclitaxel—lung cancer	0.000156	0.000726	CcSEcCtD
Dihydroergotamine—Dry mouth—Docetaxel—lung cancer	0.000155	0.000723	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000155	0.000722	CcSEcCtD
Dihydroergotamine—Fatigue—Paclitaxel—lung cancer	0.000154	0.00072	CcSEcCtD
Dihydroergotamine—Pollakiuria—Doxorubicin—lung cancer	0.000154	0.000718	CcSEcCtD
Dihydroergotamine—Asthenia—Gemcitabine—lung cancer	0.000153	0.000716	CcSEcCtD
Dihydroergotamine—Pain—Paclitaxel—lung cancer	0.000153	0.000715	CcSEcCtD
Dihydroergotamine—Confusional state—Docetaxel—lung cancer	0.000153	0.000714	CcSEcCtD
Dihydroergotamine—Pharyngitis—Methotrexate—lung cancer	0.000153	0.000713	CcSEcCtD
Dihydroergotamine—Oedema—Docetaxel—lung cancer	0.000152	0.000708	CcSEcCtD
Dihydroergotamine—Pruritus—Gemcitabine—lung cancer	0.000151	0.000706	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Etoposide—lung cancer	0.00015	0.000702	CcSEcCtD
Dihydroergotamine—Diarrhoea—Irinotecan—lung cancer	0.00015	0.000701	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Etoposide—lung cancer	0.000149	0.000697	CcSEcCtD
Dihydroergotamine—Shock—Docetaxel—lung cancer	0.000149	0.000697	CcSEcCtD
Dihydroergotamine—Visual impairment—Methotrexate—lung cancer	0.000148	0.000692	CcSEcCtD
Dihydroergotamine—Tachycardia—Docetaxel—lung cancer	0.000148	0.000691	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Paclitaxel—lung cancer	0.000147	0.000689	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Cisplatin—lung cancer	0.000147	0.000685	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Paclitaxel—lung cancer	0.000146	0.000683	CcSEcCtD
Dihydroergotamine—Diarrhoea—Gemcitabine—lung cancer	0.000146	0.000683	CcSEcCtD
Dihydroergotamine—Dizziness—Irinotecan—lung cancer	0.000145	0.000677	CcSEcCtD
Dihydroergotamine—Urticaria—Etoposide—lung cancer	0.000145	0.000677	CcSEcCtD
Dihydroergotamine—Anorexia—Docetaxel—lung cancer	0.000145	0.000675	CcSEcCtD
Dihydroergotamine—Abdominal pain—Etoposide—lung cancer	0.000144	0.000674	CcSEcCtD
Dihydroergotamine—Body temperature increased—Etoposide—lung cancer	0.000144	0.000674	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Doxorubicin—lung cancer	0.000144	0.000674	CcSEcCtD
Dihydroergotamine—Tinnitus—Methotrexate—lung cancer	0.000143	0.00067	CcSEcCtD
Dihydroergotamine—Asthenia—Cisplatin—lung cancer	0.000143	0.000667	CcSEcCtD
Dihydroergotamine—Urticaria—Paclitaxel—lung cancer	0.000142	0.000664	CcSEcCtD
Dihydroergotamine—Hypotension—Docetaxel—lung cancer	0.000142	0.000662	CcSEcCtD
Dihydroergotamine—Body temperature increased—Paclitaxel—lung cancer	0.000141	0.000661	CcSEcCtD
Dihydroergotamine—Abdominal pain—Paclitaxel—lung cancer	0.000141	0.000661	CcSEcCtD
Dihydroergotamine—Epistaxis—Doxorubicin—lung cancer	0.00014	0.000654	CcSEcCtD
Dihydroergotamine—Vomiting—Irinotecan—lung cancer	0.000139	0.000651	CcSEcCtD
Dihydroergotamine—Sinusitis—Doxorubicin—lung cancer	0.000139	0.00065	CcSEcCtD
Dihydroergotamine—Rash—Irinotecan—lung cancer	0.000138	0.000646	CcSEcCtD
Dihydroergotamine—Dermatitis—Irinotecan—lung cancer	0.000138	0.000645	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000138	0.000645	CcSEcCtD
Dihydroergotamine—Chills—Methotrexate—lung cancer	0.000138	0.000645	CcSEcCtD
Dihydroergotamine—Headache—Irinotecan—lung cancer	0.000137	0.000642	CcSEcCtD
Dihydroergotamine—Insomnia—Docetaxel—lung cancer	0.000137	0.000641	CcSEcCtD
Dihydroergotamine—Diarrhoea—Cisplatin—lung cancer	0.000136	0.000636	CcSEcCtD
Dihydroergotamine—Paraesthesia—Docetaxel—lung cancer	0.000136	0.000636	CcSEcCtD
Dihydroergotamine—Vomiting—Gemcitabine—lung cancer	0.000136	0.000635	CcSEcCtD
Dihydroergotamine—Dyspnoea—Docetaxel—lung cancer	0.000135	0.000631	CcSEcCtD
Dihydroergotamine—Somnolence—Docetaxel—lung cancer	0.000135	0.00063	CcSEcCtD
Dihydroergotamine—Rash—Gemcitabine—lung cancer	0.000135	0.000629	CcSEcCtD
Dihydroergotamine—Dermatitis—Gemcitabine—lung cancer	0.000135	0.000629	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Etoposide—lung cancer	0.000134	0.000628	CcSEcCtD
Dihydroergotamine—Headache—Gemcitabine—lung cancer	0.000134	0.000625	CcSEcCtD
Dihydroergotamine—Rhinitis—Doxorubicin—lung cancer	0.000134	0.000624	CcSEcCtD
Dihydroergotamine—Dyspepsia—Docetaxel—lung cancer	0.000133	0.000623	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Doxorubicin—lung cancer	0.000133	0.000619	CcSEcCtD
Dihydroergotamine—Pharyngitis—Doxorubicin—lung cancer	0.000132	0.000617	CcSEcCtD
Dihydroergotamine—Decreased appetite—Docetaxel—lung cancer	0.000132	0.000616	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Paclitaxel—lung cancer	0.000132	0.000616	CcSEcCtD
Dihydroergotamine—Asthenia—Etoposide—lung cancer	0.000131	0.000611	CcSEcCtD
Dihydroergotamine—Fatigue—Docetaxel—lung cancer	0.000131	0.000611	CcSEcCtD
Dihydroergotamine—Nausea—Irinotecan—lung cancer	0.00013	0.000609	CcSEcCtD
Dihydroergotamine—Pain—Docetaxel—lung cancer	0.00013	0.000606	CcSEcCtD
Dihydroergotamine—Pruritus—Etoposide—lung cancer	0.000129	0.000603	CcSEcCtD
Dihydroergotamine—Visual impairment—Doxorubicin—lung cancer	0.000128	0.0006	CcSEcCtD
Dihydroergotamine—Asthenia—Paclitaxel—lung cancer	0.000128	0.000599	CcSEcCtD
Dihydroergotamine—Nausea—Gemcitabine—lung cancer	0.000127	0.000593	CcSEcCtD
Dihydroergotamine—Vomiting—Cisplatin—lung cancer	0.000127	0.000591	CcSEcCtD
Dihydroergotamine—Pruritus—Paclitaxel—lung cancer	0.000127	0.000591	CcSEcCtD
Dihydroergotamine—Rash—Cisplatin—lung cancer	0.000126	0.000587	CcSEcCtD
Dihydroergotamine—Dermatitis—Cisplatin—lung cancer	0.000125	0.000586	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Docetaxel—lung cancer	0.000125	0.000584	CcSEcCtD
Dihydroergotamine—Diarrhoea—Etoposide—lung cancer	0.000125	0.000583	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Methotrexate—lung cancer	0.000124	0.00058	CcSEcCtD
Dihydroergotamine—Tinnitus—Doxorubicin—lung cancer	0.000124	0.00058	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Docetaxel—lung cancer	0.000124	0.000579	CcSEcCtD
Dihydroergotamine—Flushing—Doxorubicin—lung cancer	0.000124	0.000577	CcSEcCtD
Dihydroergotamine—Diarrhoea—Paclitaxel—lung cancer	0.000122	0.000572	CcSEcCtD
Dihydroergotamine—Malaise—Methotrexate—lung cancer	0.000121	0.000564	CcSEcCtD
Dihydroergotamine—Dizziness—Etoposide—lung cancer	0.000121	0.000564	CcSEcCtD
Dihydroergotamine—Vertigo—Methotrexate—lung cancer	0.00012	0.000562	CcSEcCtD
Dihydroergotamine—Body temperature increased—Docetaxel—lung cancer	0.00012	0.00056	CcSEcCtD
Dihydroergotamine—Abdominal pain—Docetaxel—lung cancer	0.00012	0.00056	CcSEcCtD
Dihydroergotamine—Chills—Doxorubicin—lung cancer	0.00012	0.000558	CcSEcCtD
Dihydroergotamine—Dizziness—Paclitaxel—lung cancer	0.000118	0.000553	CcSEcCtD
Dihydroergotamine—Nausea—Cisplatin—lung cancer	0.000118	0.000553	CcSEcCtD
Dihydroergotamine—Vomiting—Etoposide—lung cancer	0.000116	0.000542	CcSEcCtD
Dihydroergotamine—Rash—Etoposide—lung cancer	0.000115	0.000537	CcSEcCtD
Dihydroergotamine—Dermatitis—Etoposide—lung cancer	0.000115	0.000537	CcSEcCtD
Dihydroergotamine—Headache—Etoposide—lung cancer	0.000114	0.000534	CcSEcCtD
Dihydroergotamine—Myalgia—Methotrexate—lung cancer	0.000114	0.000532	CcSEcCtD
Dihydroergotamine—Arthralgia—Methotrexate—lung cancer	0.000114	0.000532	CcSEcCtD
Dihydroergotamine—Tension—Doxorubicin—lung cancer	0.000114	0.000531	CcSEcCtD
Dihydroergotamine—Vomiting—Paclitaxel—lung cancer	0.000114	0.000531	CcSEcCtD
Dihydroergotamine—Rash—Paclitaxel—lung cancer	0.000113	0.000527	CcSEcCtD
Dihydroergotamine—Dermatitis—Paclitaxel—lung cancer	0.000113	0.000526	CcSEcCtD
Dihydroergotamine—Discomfort—Methotrexate—lung cancer	0.000113	0.000526	CcSEcCtD
Dihydroergotamine—Nervousness—Doxorubicin—lung cancer	0.000113	0.000526	CcSEcCtD
Dihydroergotamine—Headache—Paclitaxel—lung cancer	0.000112	0.000523	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Docetaxel—lung cancer	0.000112	0.000522	CcSEcCtD
Dihydroergotamine—Muscle spasms—Doxorubicin—lung cancer	0.000111	0.000521	CcSEcCtD
Dihydroergotamine—Confusional state—Methotrexate—lung cancer	0.00011	0.000515	CcSEcCtD
Dihydroergotamine—Asthenia—Docetaxel—lung cancer	0.000109	0.000508	CcSEcCtD
Dihydroergotamine—Nausea—Etoposide—lung cancer	0.000108	0.000506	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Doxorubicin—lung cancer	0.000108	0.000502	CcSEcCtD
Dihydroergotamine—Pruritus—Docetaxel—lung cancer	0.000107	0.000501	CcSEcCtD
Dihydroergotamine—Agitation—Doxorubicin—lung cancer	0.000107	0.000498	CcSEcCtD
Dihydroergotamine—Nausea—Paclitaxel—lung cancer	0.000106	0.000496	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Methotrexate—lung cancer	0.000106	0.000493	CcSEcCtD
Dihydroergotamine—Malaise—Doxorubicin—lung cancer	0.000105	0.000488	CcSEcCtD
Dihydroergotamine—Vertigo—Doxorubicin—lung cancer	0.000104	0.000487	CcSEcCtD
Dihydroergotamine—Anorexia—Methotrexate—lung cancer	0.000104	0.000487	CcSEcCtD
Dihydroergotamine—Diarrhoea—Docetaxel—lung cancer	0.000104	0.000485	CcSEcCtD
Dihydroergotamine—Palpitations—Doxorubicin—lung cancer	0.000102	0.000479	CcSEcCtD
Dihydroergotamine—Hypotension—Methotrexate—lung cancer	0.000102	0.000477	CcSEcCtD
Dihydroergotamine—Dizziness—Docetaxel—lung cancer	0.0001	0.000468	CcSEcCtD
Dihydroergotamine—Hypertension—Doxorubicin—lung cancer	0.0001	0.000468	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Methotrexate—lung cancer	9.96e-05	0.000465	CcSEcCtD
Dihydroergotamine—Insomnia—Methotrexate—lung cancer	9.89e-05	0.000462	CcSEcCtD
Dihydroergotamine—Arthralgia—Doxorubicin—lung cancer	9.87e-05	0.000461	CcSEcCtD
Dihydroergotamine—Myalgia—Doxorubicin—lung cancer	9.87e-05	0.000461	CcSEcCtD
Dihydroergotamine—Anxiety—Doxorubicin—lung cancer	9.84e-05	0.000459	CcSEcCtD
Dihydroergotamine—Paraesthesia—Methotrexate—lung cancer	9.81e-05	0.000458	CcSEcCtD
Dihydroergotamine—Discomfort—Doxorubicin—lung cancer	9.75e-05	0.000456	CcSEcCtD
Dihydroergotamine—Dyspnoea—Methotrexate—lung cancer	9.74e-05	0.000455	CcSEcCtD
Dihydroergotamine—Somnolence—Methotrexate—lung cancer	9.72e-05	0.000454	CcSEcCtD
Dihydroergotamine—Dry mouth—Doxorubicin—lung cancer	9.66e-05	0.000451	CcSEcCtD
Dihydroergotamine—Vomiting—Docetaxel—lung cancer	9.64e-05	0.00045	CcSEcCtD
Dihydroergotamine—Dyspepsia—Methotrexate—lung cancer	9.62e-05	0.000449	CcSEcCtD
Dihydroergotamine—Rash—Docetaxel—lung cancer	9.56e-05	0.000447	CcSEcCtD
Dihydroergotamine—Dermatitis—Docetaxel—lung cancer	9.55e-05	0.000446	CcSEcCtD
Dihydroergotamine—Confusional state—Doxorubicin—lung cancer	9.54e-05	0.000446	CcSEcCtD
Dihydroergotamine—Decreased appetite—Methotrexate—lung cancer	9.5e-05	0.000444	CcSEcCtD
Dihydroergotamine—Headache—Docetaxel—lung cancer	9.5e-05	0.000444	CcSEcCtD
Dihydroergotamine—Oedema—Doxorubicin—lung cancer	9.46e-05	0.000442	CcSEcCtD
Dihydroergotamine—Fatigue—Methotrexate—lung cancer	9.42e-05	0.00044	CcSEcCtD
Dihydroergotamine—Pain—Methotrexate—lung cancer	9.35e-05	0.000437	CcSEcCtD
Dihydroergotamine—Shock—Doxorubicin—lung cancer	9.31e-05	0.000435	CcSEcCtD
Dihydroergotamine—Tachycardia—Doxorubicin—lung cancer	9.24e-05	0.000431	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Doxorubicin—lung cancer	9.15e-05	0.000427	CcSEcCtD
Dihydroergotamine—Anorexia—Doxorubicin—lung cancer	9.02e-05	0.000421	CcSEcCtD
Dihydroergotamine—Nausea—Docetaxel—lung cancer	9.01e-05	0.000421	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Methotrexate—lung cancer	9.01e-05	0.000421	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Methotrexate—lung cancer	8.94e-05	0.000417	CcSEcCtD
Dihydroergotamine—Hypotension—Doxorubicin—lung cancer	8.84e-05	0.000413	CcSEcCtD
Dihydroergotamine—Urticaria—Methotrexate—lung cancer	8.68e-05	0.000406	CcSEcCtD
Dihydroergotamine—Body temperature increased—Methotrexate—lung cancer	8.64e-05	0.000404	CcSEcCtD
Dihydroergotamine—Abdominal pain—Methotrexate—lung cancer	8.64e-05	0.000404	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Doxorubicin—lung cancer	8.62e-05	0.000403	CcSEcCtD
Dihydroergotamine—Insomnia—Doxorubicin—lung cancer	8.56e-05	0.0004	CcSEcCtD
Dihydroergotamine—Paraesthesia—Doxorubicin—lung cancer	8.5e-05	0.000397	CcSEcCtD
Dihydroergotamine—Dyspnoea—Doxorubicin—lung cancer	8.44e-05	0.000394	CcSEcCtD
Dihydroergotamine—Somnolence—Doxorubicin—lung cancer	8.41e-05	0.000393	CcSEcCtD
Dihydroergotamine—Dyspepsia—Doxorubicin—lung cancer	8.33e-05	0.000389	CcSEcCtD
Dihydroergotamine—Decreased appetite—Doxorubicin—lung cancer	8.23e-05	0.000384	CcSEcCtD
Dihydroergotamine—Fatigue—Doxorubicin—lung cancer	8.16e-05	0.000381	CcSEcCtD
Dihydroergotamine—Pain—Doxorubicin—lung cancer	8.09e-05	0.000378	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Methotrexate—lung cancer	8.05e-05	0.000376	CcSEcCtD
Dihydroergotamine—Asthenia—Methotrexate—lung cancer	7.84e-05	0.000366	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Doxorubicin—lung cancer	7.8e-05	0.000364	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Doxorubicin—lung cancer	7.74e-05	0.000361	CcSEcCtD
Dihydroergotamine—Pruritus—Methotrexate—lung cancer	7.73e-05	0.000361	CcSEcCtD
Dihydroergotamine—Urticaria—Doxorubicin—lung cancer	7.52e-05	0.000351	CcSEcCtD
Dihydroergotamine—Abdominal pain—Doxorubicin—lung cancer	7.48e-05	0.000349	CcSEcCtD
Dihydroergotamine—Body temperature increased—Doxorubicin—lung cancer	7.48e-05	0.000349	CcSEcCtD
Dihydroergotamine—Diarrhoea—Methotrexate—lung cancer	7.48e-05	0.000349	CcSEcCtD
Dihydroergotamine—Dizziness—Methotrexate—lung cancer	7.23e-05	0.000338	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Doxorubicin—lung cancer	6.97e-05	0.000326	CcSEcCtD
Dihydroergotamine—Vomiting—Methotrexate—lung cancer	6.95e-05	0.000325	CcSEcCtD
Dihydroergotamine—Rash—Methotrexate—lung cancer	6.89e-05	0.000322	CcSEcCtD
Dihydroergotamine—Dermatitis—Methotrexate—lung cancer	6.89e-05	0.000322	CcSEcCtD
Dihydroergotamine—Headache—Methotrexate—lung cancer	6.85e-05	0.00032	CcSEcCtD
Dihydroergotamine—Asthenia—Doxorubicin—lung cancer	6.79e-05	0.000317	CcSEcCtD
Dihydroergotamine—Pruritus—Doxorubicin—lung cancer	6.7e-05	0.000313	CcSEcCtD
Dihydroergotamine—Nausea—Methotrexate—lung cancer	6.49e-05	0.000303	CcSEcCtD
Dihydroergotamine—Diarrhoea—Doxorubicin—lung cancer	6.48e-05	0.000302	CcSEcCtD
Dihydroergotamine—Dizziness—Doxorubicin—lung cancer	6.26e-05	0.000292	CcSEcCtD
Dihydroergotamine—Vomiting—Doxorubicin—lung cancer	6.02e-05	0.000281	CcSEcCtD
Dihydroergotamine—Rash—Doxorubicin—lung cancer	5.97e-05	0.000279	CcSEcCtD
Dihydroergotamine—Dermatitis—Doxorubicin—lung cancer	5.96e-05	0.000278	CcSEcCtD
Dihydroergotamine—Headache—Doxorubicin—lung cancer	5.93e-05	0.000277	CcSEcCtD
Dihydroergotamine—Nausea—Doxorubicin—lung cancer	5.62e-05	0.000263	CcSEcCtD
Dihydroergotamine—HTR2B—Signaling Pathways—MTOR—lung cancer	8.39e-06	0.000126	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CB—lung cancer	8.39e-06	0.000126	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CASP3—lung cancer	8.39e-06	0.000126	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL2—lung cancer	8.38e-06	0.000126	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALDOA—lung cancer	8.37e-06	0.000126	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—BRAF—lung cancer	8.35e-06	0.000126	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CG—lung cancer	8.35e-06	0.000126	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—lung cancer	8.33e-06	0.000125	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL2—lung cancer	8.31e-06	0.000125	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT1—lung cancer	8.29e-06	0.000125	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TERT—lung cancer	8.28e-06	0.000125	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6R—lung cancer	8.24e-06	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CREBBP—lung cancer	8.23e-06	0.000124	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CAT—lung cancer	8.23e-06	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCND1—lung cancer	8.23e-06	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CASP3—lung cancer	8.21e-06	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—JUN—lung cancer	8.21e-06	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL2—lung cancer	8.2e-06	0.000123	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCND1—lung cancer	8.17e-06	0.000123	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—lung cancer	8.16e-06	0.000123	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—JUN—lung cancer	8.15e-06	0.000123	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NCOA3—lung cancer	8.12e-06	0.000122	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—EGFR—lung cancer	8.09e-06	0.000122	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCL8—lung cancer	8.06e-06	0.000121	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGFR1—lung cancer	8.04e-06	0.000121	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HRAS—lung cancer	8.01e-06	0.000121	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCND1—lung cancer	8e-06	0.00012	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MMP9—lung cancer	7.99e-06	0.00012	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—JUN—lung cancer	7.98e-06	0.00012	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CDKN1A—lung cancer	7.96e-06	0.00012	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—POMC—lung cancer	7.94e-06	0.00012	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PTEN—lung cancer	7.94e-06	0.00012	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MMP9—lung cancer	7.93e-06	0.000119	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HIF1A—lung cancer	7.92e-06	0.000119	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ADCY1—lung cancer	7.9e-06	0.000119	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ABCG2—lung cancer	7.9e-06	0.000119	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CDKN1A—lung cancer	7.9e-06	0.000119	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PTEN—lung cancer	7.88e-06	0.000119	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TYMS—lung cancer	7.86e-06	0.000118	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAP2K1—lung cancer	7.86e-06	0.000118	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT1—lung cancer	7.85e-06	0.000118	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CD—lung cancer	7.8e-06	0.000117	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT1—lung cancer	7.79e-06	0.000117	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTM1—lung cancer	7.77e-06	0.000117	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MMP9—lung cancer	7.76e-06	0.000117	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ENO2—lung cancer	7.75e-06	0.000117	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HPGDS—lung cancer	7.75e-06	0.000117	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT1—lung cancer	7.75e-06	0.000117	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CREBBP—lung cancer	7.74e-06	0.000116	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CDKN1A—lung cancer	7.73e-06	0.000116	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—PIK3CA—lung cancer	7.73e-06	0.000116	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PTEN—lung cancer	7.72e-06	0.000116	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CASP3—lung cancer	7.72e-06	0.000116	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL2—lung cancer	7.7e-06	0.000116	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPP2R1B—lung cancer	7.7e-06	0.000116	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT1—lung cancer	7.69e-06	0.000116	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—lung cancer	7.67e-06	0.000115	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOA1—lung cancer	7.64e-06	0.000115	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—KRAS—lung cancer	7.64e-06	0.000115	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KDR—lung cancer	7.57e-06	0.000114	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EP300—lung cancer	7.57e-06	0.000114	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT1—lung cancer	7.53e-06	0.000113	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTT1—lung cancer	7.52e-06	0.000113	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EP300—lung cancer	7.52e-06	0.000113	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCND1—lung cancer	7.51e-06	0.000113	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—JUN—lung cancer	7.49e-06	0.000113	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GCLC—lung cancer	7.43e-06	0.000112	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2A6—lung cancer	7.43e-06	0.000112	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP1A1—lung cancer	7.37e-06	0.000111	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SRC—lung cancer	7.36e-06	0.000111	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EP300—lung cancer	7.36e-06	0.000111	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CD—lung cancer	7.34e-06	0.00011	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SRC—lung cancer	7.31e-06	0.00011	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ERCC2—lung cancer	7.31e-06	0.00011	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MMP9—lung cancer	7.29e-06	0.00011	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CDKN1A—lung cancer	7.27e-06	0.000109	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PTEN—lung cancer	7.25e-06	0.000109	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALB—lung cancer	7.24e-06	0.000109	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—VEGFA—lung cancer	7.17e-06	0.000108	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SRC—lung cancer	7.16e-06	0.000108	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—VEGFA—lung cancer	7.12e-06	0.000107	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—STAT3—lung cancer	7.1e-06	0.000107	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NRAS—lung cancer	7.09e-06	0.000107	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT1—lung cancer	7.07e-06	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—STAT3—lung cancer	7.05e-06	0.000106	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ENO1—lung cancer	7.04e-06	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NRAS—lung cancer	7.03e-06	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PIK3CA—lung cancer	7.02e-06	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MDM2—lung cancer	6.99e-06	0.000105	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CG—lung cancer	6.98e-06	0.000105	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KIT—lung cancer	6.98e-06	0.000105	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APC—lung cancer	6.98e-06	0.000105	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—NRAS—lung cancer	6.98e-06	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—VEGFA—lung cancer	6.97e-06	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—RAF1—lung cancer	6.97e-06	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EP300—lung cancer	6.91e-06	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—STAT3—lung cancer	6.9e-06	0.000104	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGF—lung cancer	6.9e-06	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ERBB2—lung cancer	6.89e-06	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NRAS—lung cancer	6.88e-06	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MTOR—lung cancer	6.8e-06	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CB—lung cancer	6.8e-06	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK3—lung cancer	6.79e-06	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK3—lung cancer	6.73e-06	0.000101	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SRC—lung cancer	6.72e-06	0.000101	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—MAPK3—lung cancer	6.68e-06	0.000101	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—POMC—lung cancer	6.64e-06	0.0001	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MYC—lung cancer	6.6e-06	9.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK3—lung cancer	6.59e-06	9.92e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—BRAF—lung cancer	6.56e-06	9.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MYC—lung cancer	6.55e-06	9.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—VEGFA—lung cancer	6.55e-06	9.85e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCL8—lung cancer	6.54e-06	9.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HRAS—lung cancer	6.5e-06	9.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—STAT3—lung cancer	6.48e-06	9.76e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6R—lung cancer	6.48e-06	9.75e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CREBBP—lung cancer	6.47e-06	9.74e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NRAS—lung cancer	6.47e-06	9.73e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EGFR—lung cancer	6.46e-06	9.72e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MYC—lung cancer	6.41e-06	9.65e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EGFR—lung cancer	6.41e-06	9.64e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CB—lung cancer	6.39e-06	9.62e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—EGFR—lung cancer	6.36e-06	9.57e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—lung cancer	6.34e-06	9.54e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOA1—lung cancer	6.32e-06	9.51e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2E1—lung cancer	6.32e-06	9.51e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT1—lung cancer	6.32e-06	9.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EGFR—lung cancer	6.27e-06	9.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CASP3—lung cancer	6.26e-06	9.42e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL2—lung cancer	6.25e-06	9.4e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NQO1—lung cancer	6.25e-06	9.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—lung cancer	6.22e-06	9.36e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK3—lung cancer	6.19e-06	9.32e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	6.18e-06	9.29e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	6.13e-06	9.23e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—KRAS—lung cancer	6.1e-06	9.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCND1—lung cancer	6.09e-06	9.17e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—JUN—lung cancer	6.08e-06	9.15e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	6.08e-06	9.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—KRAS—lung cancer	6.05e-06	9.11e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MYC—lung cancer	6.02e-06	9.07e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—KRAS—lung cancer	6.01e-06	9.04e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—KRAS—lung cancer	5.93e-06	8.92e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MMP9—lung cancer	5.91e-06	8.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EGFR—lung cancer	5.89e-06	8.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDKN1A—lung cancer	5.89e-06	8.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PTEN—lung cancer	5.88e-06	8.85e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CG—lung cancer	5.77e-06	8.69e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT1—lung cancer	5.73e-06	8.63e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—STK11—lung cancer	5.63e-06	8.48e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EP300—lung cancer	5.61e-06	8.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CA—lung cancer	5.6e-06	8.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—KRAS—lung cancer	5.57e-06	8.38e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CA—lung cancer	5.56e-06	8.37e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTEN—lung cancer	5.53e-06	8.32e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	5.52e-06	8.3e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MDM2—lung cancer	5.5e-06	8.27e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—POMC—lung cancer	5.49e-06	8.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RAF1—lung cancer	5.48e-06	8.24e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SRC—lung cancer	5.45e-06	8.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CA—lung cancer	5.44e-06	8.19e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TP53—lung cancer	5.42e-06	8.16e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ERBB2—lung cancer	5.42e-06	8.15e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TP53—lung cancer	5.38e-06	8.1e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CREBBP—lung cancer	5.35e-06	8.05e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MTOR—lung cancer	5.35e-06	8.05e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	5.35e-06	8.05e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—VEGFA—lung cancer	5.31e-06	7.99e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—EP300—lung cancer	5.27e-06	7.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TP53—lung cancer	5.27e-06	7.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—STAT3—lung cancer	5.26e-06	7.91e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NRAS—lung cancer	5.24e-06	7.89e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTP1—lung cancer	5.21e-06	7.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HRAS—lung cancer	5.18e-06	7.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HRAS—lung cancer	5.14e-06	7.74e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL8—lung cancer	5.14e-06	7.73e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CA—lung cancer	5.11e-06	7.7e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HRAS—lung cancer	5.1e-06	7.68e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CD—lung cancer	5.07e-06	7.64e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CAT—lung cancer	5.07e-06	7.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HRAS—lung cancer	5.04e-06	7.58e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK3—lung cancer	5.02e-06	7.56e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALB—lung cancer	5.01e-06	7.54e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	4.96e-06	7.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—lung cancer	4.96e-06	7.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TP53—lung cancer	4.95e-06	7.45e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ABCB1—lung cancer	4.93e-06	7.42e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—lung cancer	4.92e-06	7.41e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CASP3—lung cancer	4.92e-06	7.4e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL2—lung cancer	4.91e-06	7.39e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—lung cancer	4.89e-06	7.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MYC—lung cancer	4.89e-06	7.35e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TYMS—lung cancer	4.84e-06	7.29e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—lung cancer	4.82e-06	7.26e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTM1—lung cancer	4.79e-06	7.21e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCND1—lung cancer	4.79e-06	7.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EGFR—lung cancer	4.78e-06	7.19e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—JUN—lung cancer	4.78e-06	7.19e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HRAS—lung cancer	4.73e-06	7.12e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP9—lung cancer	4.65e-06	6.99e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	4.63e-06	6.97e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTEN—lung cancer	4.62e-06	6.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT1—lung cancer	4.58e-06	6.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT1—lung cancer	4.54e-06	6.84e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP1A1—lung cancer	4.54e-06	6.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—lung cancer	4.53e-06	6.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KRAS—lung cancer	4.51e-06	6.79e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT1—lung cancer	4.51e-06	6.78e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ERCC2—lung cancer	4.5e-06	6.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT1—lung cancer	4.45e-06	6.69e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CB—lung cancer	4.42e-06	6.66e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EP300—lung cancer	4.41e-06	6.63e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—lung cancer	4.38e-06	6.59e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SRC—lung cancer	4.28e-06	6.45e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT1—lung cancer	4.18e-06	6.29e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—VEGFA—lung cancer	4.17e-06	6.28e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CA—lung cancer	4.15e-06	6.24e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STAT3—lung cancer	4.13e-06	6.22e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NRAS—lung cancer	4.12e-06	6.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TP53—lung cancer	4.01e-06	6.04e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK3—lung cancer	3.95e-06	5.94e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CA—lung cancer	3.9e-06	5.87e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOA1—lung cancer	3.89e-06	5.86e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MYC—lung cancer	3.84e-06	5.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HRAS—lung cancer	3.84e-06	5.77e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTEN—lung cancer	3.82e-06	5.75e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGFR—lung cancer	3.76e-06	5.65e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—lung cancer	3.67e-06	5.53e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—EP300—lung cancer	3.64e-06	5.48e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CG—lung cancer	3.56e-06	5.35e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KRAS—lung cancer	3.55e-06	5.34e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT1—lung cancer	3.39e-06	5.1e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—POMC—lung cancer	3.38e-06	5.09e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CREBBP—lung cancer	3.3e-06	4.96e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	3.26e-06	4.91e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKT1—lung cancer	3.18e-06	4.79e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TP53—lung cancer	3.15e-06	4.75e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CD—lung cancer	3.13e-06	4.7e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALB—lung cancer	3.09e-06	4.64e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HRAS—lung cancer	3.02e-06	4.54e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—lung cancer	2.89e-06	4.34e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CB—lung cancer	2.72e-06	4.1e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—lung cancer	2.7e-06	4.06e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CA—lung cancer	2.7e-06	4.06e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT1—lung cancer	2.66e-06	4.01e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTEN—lung cancer	2.35e-06	3.54e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—EP300—lung cancer	2.25e-06	3.38e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKT1—lung cancer	2.2e-06	3.31e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CA—lung cancer	1.66e-06	2.5e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKT1—lung cancer	1.36e-06	2.04e-05	CbGpPWpGaD
